Advertisement
Screener

BIOGEN INC. (BIIB) Goodwill, Other Increase (Decrease)

2.8 / 5 stars · 68/120 Roast Me

BIOGEN INC. Goodwill, Other Increase (Decrease)

BIOGEN INC. (BIIB) reported Goodwill, Other Increase (Decrease) of -$2.40 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.

Financial Statements › Notes › Goodwill and Other

us-gaap:GoodwillOtherIncreaseDecrease · last filed 2026-04-29

  • BIOGEN INC. goodwill, other increase (decrease) for the quarter ending 2026-03-31 was -$2.40M, a 172.73% decline year-over-year.
  • BIOGEN INC. goodwill, other increase (decrease) for the quarter ending 2025-12-31 was $400.00K.
  • BIOGEN INC. goodwill, other increase (decrease) for the quarter ending 2025-09-30 was -$2.40M, a 138.71% decline year-over-year.
  • BIOGEN INC. goodwill, other increase (decrease) for the quarter ending 2025-06-30 was $6.40M.
  • BIOGEN INC. goodwill, other increase (decrease) for fiscal 2025 was $7.70M.
  • BIOGEN INC. goodwill, other increase (decrease) for fiscal 2024 was -$1.50M, a 126.32% decline from fiscal 2023.
  • BIOGEN INC. goodwill, other increase (decrease) for fiscal 2023 was $5.70M.
  • BIOGEN INC. goodwill, other increase (decrease) for fiscal 2022 was -$12.10M.
Period endGoodwill, Other Increase (Decrease) 3 monthGoodwill, Other Increase (Decrease) 6 monthGoodwill, Other Increase (Decrease) 9 monthGoodwill, Other Increase (Decrease) 12 month
2026-03-31-$2.40M
10-Q · filed 2026-04-29
-$2.00M
derived: sum of 2 quarters · filed 2026-04-29
-$4.40M
derived: sum of 3 quarters · filed 2026-04-29
$2.00M
derived: sum of 4 quarters · filed 2026-04-29
2025-12-31$400.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06
-$2.00M
derived: sum of 2 quarters · filed 2026-02-06
$4.40M
derived: sum of 3 quarters · filed 2026-02-06
$7.70M
10-K · filed 2026-02-06
2025-09-30-$2.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30
$4.00M
derived: sum of 2 quarters · filed 2025-10-30
$7.30M
10-Q · filed 2025-10-30
$400.00K
derived: sum of 4 quarters · filed 2026-02-06
2025-06-30$6.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31
$9.70M
10-Q · filed 2025-07-31
$2.80M
derived: sum of 3 quarters · filed 2026-02-06
$9.00M
derived: sum of 4 quarters · filed 2026-02-06
2025-03-31$3.30M
10-Q · filed 2025-05-01
-$3.60M
derived: sum of 2 quarters · filed 2026-02-06
$2.60M
derived: sum of 3 quarters · filed 2026-02-06
$2.60M
derived: sum of 4 quarters · filed 2026-02-06
2024-12-31-$6.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06
-$700.00K
derived: sum of 2 quarters · filed 2026-02-06
-$700.00K
derived: sum of 3 quarters · filed 2026-02-06
-$1.50M
10-K · filed 2026-02-06
2024-09-30$6.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30
$6.20M
derived: sum of 2 quarters · filed 2024-10-30
$5.40M
10-Q · filed 2024-10-30
$9.90M
derived: sum of 4 quarters · filed 2025-02-12
2024-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
-$800.00K
10-Q · filed 2024-08-01
$3.70M
derived: sum of 3 quarters · filed 2025-02-12
$200.00K
derived: sum of 4 quarters · filed 2025-02-12
2024-03-31-$800.00K
10-Q · filed 2024-04-24
$3.70M
derived: sum of 2 quarters · filed 2025-02-12
$200.00K
derived: sum of 3 quarters · filed 2025-02-12
$2.10M
derived: sum of 4 quarters · filed 2025-02-12
2023-12-31$4.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12
$1.00M
derived: sum of 2 quarters · filed 2025-02-12
$2.90M
derived: sum of 3 quarters · filed 2025-02-12
$5.70M
10-K · filed 2025-02-12
2023-09-30-$3.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
-$1.60M
derived: sum of 2 quarters · filed 2023-11-08
$1.20M
10-Q · filed 2023-11-08
$9.00M
derived: sum of 4 quarters · filed 2024-02-14
2023-06-30$1.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25
$4.70M
10-Q · filed 2023-07-25
$12.50M
derived: sum of 3 quarters · filed 2024-02-14
$4.10M
derived: sum of 4 quarters · filed 2024-02-14
2023-03-31$2.80M
10-Q · filed 2023-04-25
$10.60M
derived: sum of 2 quarters · filed 2024-02-14
$2.20M
derived: sum of 3 quarters · filed 2024-02-14
-$6.20M
derived: sum of 4 quarters · filed 2024-02-14
2022-12-31$7.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14
-$600.00K
derived: sum of 2 quarters · filed 2024-02-14
-$9.00M
derived: sum of 3 quarters · filed 2024-02-14
-$12.10M
10-K · filed 2024-02-14
2022-09-30-$8.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25
-$16.80M
derived: sum of 2 quarters · filed 2022-10-25
-$19.90M
10-Q · filed 2022-10-25
-$19.30M
derived: sum of 4 quarters · filed 2023-02-15
2022-06-30-$8.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20
-$11.50M
10-Q · filed 2022-07-20
-$10.90M
derived: sum of 3 quarters · filed 2023-02-15
-$14.30M
derived: sum of 4 quarters · filed 2023-02-15
2022-03-31-$3.10M
10-Q · filed 2022-05-03
-$2.50M
derived: sum of 2 quarters · filed 2023-02-15
-$5.90M
derived: sum of 3 quarters · filed 2023-02-15
-$5.10M
derived: sum of 4 quarters · filed 2023-02-15
2021-12-31$600.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15
-$2.80M
derived: sum of 2 quarters · filed 2023-02-15
-$2.00M
derived: sum of 3 quarters · filed 2023-02-15
-$1.00M
10-K · filed 2023-02-15
2021-09-30-$3.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20
-$2.60M
derived: sum of 2 quarters · filed 2021-10-20
-$1.60M
10-Q · filed 2021-10-20
$4.80M
derived: sum of 4 quarters · filed 2022-02-03
2021-06-30$800.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-22
$1.80M
10-Q · filed 2021-07-22
$8.20M
derived: sum of 3 quarters · filed 2022-02-03
$12.90M
derived: sum of 4 quarters · filed 2022-02-03
2021-03-31$1.00M
10-Q · filed 2021-04-22
$7.40M
derived: sum of 2 quarters · filed 2022-02-03
$12.10M
derived: sum of 3 quarters · filed 2022-02-03
$11.10M
derived: sum of 4 quarters · filed 2022-02-03
2020-12-31$6.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03
$11.10M
derived: sum of 2 quarters · filed 2022-02-03
$10.10M
derived: sum of 3 quarters · filed 2022-02-03
$4.30M
10-K · filed 2022-02-03
2020-09-30$4.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21
$3.70M
derived: sum of 2 quarters · filed 2020-10-21
-$2.10M
10-Q · filed 2020-10-21
$4.70M
derived: sum of 4 quarters · filed 2021-02-03
2020-06-30-$1.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-22
-$6.80M
10-Q · filed 2020-07-22
$0.00
derived: sum of 3 quarters · filed 2021-02-03
-$3.10M
derived: sum of 4 quarters · filed 2021-02-03
2020-03-31-$5.80M
10-Q · filed 2020-04-23
$1.00M
derived: sum of 2 quarters · filed 2021-02-03
-$2.10M
derived: sum of 3 quarters · filed 2021-02-03
-$5.20M
derived: sum of 4 quarters · filed 2021-02-03
2019-12-31$6.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03
$3.70M
derived: sum of 2 quarters · filed 2021-02-03
$600.00K
derived: sum of 3 quarters · filed 2021-02-03
$3.40M
10-K · filed 2021-02-03
2019-09-30-$3.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22
-$6.20M
derived: sum of 2 quarters · filed 2019-10-22
-$3.40M
10-Q · filed 2019-10-22
-$6.50M
derived: sum of 4 quarters · filed 2020-02-06
2019-06-30-$3.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24
-$300.00K
10-Q · filed 2019-07-24
-$3.40M
derived: sum of 3 quarters · filed 2020-02-06
-$3.40M
derived: sum of 4 quarters · filed 2020-02-06
2019-03-31$2.80M
10-Q · filed 2019-04-24
-$300.00K
derived: sum of 2 quarters · filed 2020-02-06
-$300.00K
derived: sum of 3 quarters · filed 2020-02-06
-$8.20M
derived: sum of 4 quarters · filed 2020-02-06
2018-12-31-$3.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06
-$3.10M
derived: sum of 2 quarters · filed 2020-02-06
-$11.00M
derived: sum of 3 quarters · filed 2020-02-06
-$6.20M
10-K · filed 2020-02-06
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23
-$7.90M
derived: sum of 2 quarters · filed 2018-10-23
-$3.10M
10-Q · filed 2018-10-23
-$3.00M
derived: sum of 4 quarters · filed 2019-02-06
2018-06-30-$7.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-24
-$3.10M
10-Q · filed 2018-07-24
-$3.00M
derived: sum of 3 quarters · filed 2019-02-06
$600.00K
derived: sum of 4 quarters · filed 2019-02-06
2018-03-31$4.80M
10-Q · filed 2018-04-24
$4.90M
derived: sum of 2 quarters · filed 2019-02-06
$8.50M
derived: sum of 3 quarters · filed 2019-02-06
$13.00M
derived: sum of 4 quarters · filed 2019-02-06
2017-12-31$100.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06
$3.70M
derived: sum of 2 quarters · filed 2019-02-06
$8.20M
derived: sum of 3 quarters · filed 2019-02-06
$10.00M
10-K · filed 2019-02-06
2017-09-30$3.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-24
$8.10M
derived: sum of 2 quarters · filed 2017-10-24
$9.90M
10-Q · filed 2017-10-24
$3.90M
derived: sum of 4 quarters · filed 2018-02-01
2017-06-30$4.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-25
$6.30M
10-Q · filed 2017-07-25
$300.00K
derived: sum of 3 quarters · filed 2018-02-01
-$3.40M
derived: sum of 4 quarters · filed 2018-02-01
2017-03-31$1.80M
10-Q · filed 2017-04-25
-$4.20M
derived: sum of 2 quarters · filed 2018-02-01
-$7.90M
derived: sum of 3 quarters · filed 2018-02-01
-$15.90M
derived: sum of 4 quarters · filed 2018-02-01
2016-12-31-$6.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01
-$9.70M
derived: sum of 2 quarters · filed 2018-02-01
-$17.70M
derived: sum of 3 quarters · filed 2018-02-01
-$21.40M
10-K · filed 2018-02-01
2016-09-30-$3.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26
-$11.70M
derived: sum of 2 quarters · filed 2016-10-26
-$15.40M
10-Q · filed 2016-10-26
2016-06-30-$8.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-21
-$11.70M
10-Q · filed 2016-07-21
2016-03-31-$3.70M
10-Q · filed 2016-04-21
2015-12-31-$4.50M
10-K · filed 2017-02-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29